India's Ozempic Race Has Begun. Here Are the Companies Running Fastest.

Something quietly extraordinary happened in India on March 20, 2026.

No press conference. No government announcement. No breaking news ticker. Just a patent, silently expiring in the middle of the night, like a lock falling off a door that hundreds of millions of people have been waiting behind for years.

But before we get to what happened that morning, let us take a step back. Because to understand why a single patent expiry can shake an entire industry, you need to understand how patents work in pharma.

When a pharmaceutical company invents a new drug, it files a patent that gives it the exclusive right to manufacture and sell that drug, typically for 20 years from the date of filing. No competitor can legally copy it during that period. This exclusivity is the reward for the enormous cost and risk of drug discovery, which can run into billions of dollars and take over a decade before a single patient is treated. Once the patent expires, however, the door opens. Any manufacturer can produce the same molecule, sell it under a different brand name, and compete purely on price. These copies are called generics. And in India, the moment a patent falls, generics arrive fast and they arrive cheap.

That is exactly what happened on March 20, 2026, when the patent on semaglutide expired in India.

Now, semaglutide is a name worth pausing on. It is not a brand. It is a molecule, a chemical compound, the active ingredient at the heart of some of the most commercially successful drugs in pharmaceutical history. Novo Nordisk, the Danish drugmaker that invented it, sells semaglutide under two brand names. Ozempic, which is approved for Type 2 diabetes, and Wegovy, which is approved specifically for weight management. Same molecule. Different doses. Different brand names. Different prices. Think of semaglutide as the engine and Ozempic or Wegovy as the car it powers.

By morning on March 20, the pharmaceutical industry had already moved. Sun Pharma, Dr. Reddy's, Zydus, Glenmark, Natco, Cipla, and a dozen others had launched their own versions of semaglutide. The price of treatment, which had sat comfortably at 11,000 rupees a month under Novo Nordisk's brands, was now available for as little as 1,290 rupees.

That is not a discount. That is a demolition.

A Drug That Does Far More Than You Think

When most people hear about Ozempic or Wegovy, they think: weight loss. Celebrities are using it to get thinner. Social media debates about fairness and vanity. That framing is both accurate and wildly incomplete.

Semaglutide belongs to a class of medicines called GLP-1 receptor agonists. GLP-1, which stands for glucagon-like peptide-1, is a hormone your gut releases after you eat. It tells your brain you are full, slows down how quickly your stomach empties, and triggers insulin release from the pancreas. Novo Nordisk developed semaglutide as a refinement of an earlier GLP-1 drug called liraglutide, which had to be injected daily. Semaglutide was a significant upgrade. It only needed to be injected once a week, and clinical studies showed it produced greater weight loss.

The FDA approved it for diabetes in 2017 under the brand name Ozempic and for weight management in 2021 under the brand name Wegovy. But what has happened since then is scientifically remarkable.

In 2024, semaglutide became the first weight-loss medication to be approved for reducing the risk of major adverse cardiovascular events in adults with obesity, based on a landmark trial called SELECT that studied over 17,000 patients. That is not a minor footnote. That is a drug going from treating a metabolic condition to preventing heart attacks.

It did not stop there. In early 2025, semaglutide received FDA approval to reduce the risk of kidney disease worsening and kidney failure in adults with Type 2 diabetes and chronic kidney disease. Later that year, Wegovy became the first GLP-1 drug to be approved for a serious liver disease called metabolic dysfunction-associated steatohepatitis.

Scientists are now exploring the benefits of these drugs for heart failure, obstructive sleep apnea, chronic liver disease, Alzheimer's disease, addiction, and even depression. Researchers at major hospitals have proposed at scientific conferences that GLP-1 drugs may be the first true longevity drugs, medicines that address not just a single disease but the underlying metabolic processes that drive aging itself. That is an extraordinary claim and it will take years of research to validate. But it tells you how seriously the scientific community is taking this class of drugs.

The global GLP-1 market was valued at over 53 billion dollars in 2024 and is projected to nearly triple by 2030, according to healthcare market research data. This is not a niche pharmaceutical story. This is one of the biggest shifts in medicine in a generation.

What the Patent Expiry Actually Means for India

Semaglutide will remain under patent in many countries until the early 2030s. However, its patent is expiring in several large countries starting in 2025 and 2026, including India, Canada, China, Brazil, and Turkey. Together, these markets make up roughly 40 percent of the world's population and around a third of the global population of adults living with obesity.

India moved first and fastest.

More than 40 Indian pharmaceutical companies are preparing to launch their own versions of semaglutide, with prices having already collapsed from the 10,000 to 16,000 rupees a month range for Novo Nordisk's branded versions to as little as 1,290 rupees for the cheapest generics.

The scale of the need makes this urgent. According to the International Diabetes Federation, an estimated 90 million adults in India were living with diabetes in 2024, making India the second-most affected country in the world after China. That number is projected to reach 156 million by 2050. India also has one of the world's largest populations of adults with obesity, and that number is growing rapidly with urbanisation, sedentary lifestyles, and carbohydrate-heavy diets.

And yet, before the patent expired, only around 200,000 patients were on GLP-1 therapy in India despite this enormous eligible population. Two hundred thousand out of ninety million diabetics. The gap between access and need is not a crack. It is a canyon.

The War at the Top: Novo Nordisk vs Eli Lilly

Before we get to the Indian companies, there is a global competitive story that is moving fast and has direct consequences for what happens here.

Novo Nordisk was, until recently, one of the most dominant pharmaceutical companies in the world. At its peak, the company's market capitalisation briefly made it the most valuable company in Europe. Its semaglutide drugs were growing at 40 percent annually. Everything looked unstoppable.

Then Eli Lilly arrived with tirzepatide, sold under the brand names Mounjaro for diabetes and Zepbound for weight loss.

Tirzepatide is a dual agonist, meaning it mimics two hormones simultaneously, GLP-1 and another called GIP. The result is even greater weight loss than semaglutide. In a head-to-head clinical trial conducted in 2024, patients on Zepbound lost an average of 50 pounds over 72 weeks compared to 33 pounds for those on Wegovy. That gap mattered enormously to patients, doctors, and investors alike.

By the end of 2025, Eli Lilly held nearly two-thirds of US branded anti-obesity prescription market share. Tirzepatide became the world's best-selling drug molecule. The reversal in competitive positioning was stunning in its speed.

The impact on Novo Nordisk was severe. Its stock fell nearly 50 percent across 2025 and hit its lowest point in four years. Novo's next-generation drug, a combination called CagriSema designed to produce even greater weight loss, was meant to be the answer. It failed. Trial results showed it achieved 23 percent weight loss compared to 25.5 percent with tirzepatide, falling short of its goal and sending Novo's stock down another 16 percent in a single day.

Eli Lilly, meanwhile, guided 2026 revenue at over 80 billion dollars, implying roughly 25 percent growth. Novo guided for a decline.

The race at the top of the GLP-1 market remains wide open, with next-generation drugs like orforglipron, retatrutide, and survodutide all in advanced clinical trials. But the narrative has shifted decisively. Semaglutide, the molecule that created this category, now faces competition from multiple directions: a superior rival drug at the premium end, and an army of generic manufacturers at the affordable end.

India is where the generic story gets interesting.

Who Is Moving and How

This is not a story of one or two companies making cautious bets. This is the Indian pharmaceutical industry mobilising at scale, the way it has historically done when a major opportunity opens up.

Natco Pharma and its commercialisation partner Eris Lifesciences moved on day one, launching under brands including Semanat and Sundae in vial format at 1,290 rupees per month for starter doses, with a pre-filled pen device expected to follow at around 4,000 to 4,500 rupees per month.

Sun Pharmaceutical Industries, India's largest pharma company, received regulatory approval and launched under the brand Noveltreat in five dose strengths via a pre-filled pen. Sun is positioning the drug as a cardiometabolic therapy, reflecting the broader clinical evidence that has built up around the molecule.

Dr. Reddy's Laboratories received DCGI approval and has announced plans to launch 12 million pens in its first year, with an eye on 87 countries as patents fall in different markets globally. This is not a domestic play. Dr. Reddy's is treating India as a manufacturing and regulatory launchpad for a worldwide generic rollout.

Zydus Lifesciences and Lupin took an interesting partnership route rather than competing as separate entities. They announced a licensing and co-marketing agreement that brings five brands into the Indian market between them, with Semaglyn, Mashema, and Alterme from Zydus, and Semanext and Livarise from Lupin. Lupin gets the drug and the distribution reach. Zydus gets licensing fees and milestone payments. Both get market presence without the full cost of going it alone.

Glenmark entered with one of the lowest launch prices in the market, positioning aggressively for volume over margin. Alkem, Mankind, Cipla, and Biocon are either already in or actively rolling out their versions.

Biocon has made the most capital-intensive bet. The company has commissioned an injectables facility in Bengaluru specifically designed to serve both domestic and international markets, a sign that Biocon is thinking well beyond India's borders.

Meanwhile, Eli Lilly's Mounjaro, which entered India with tirzepatide, became India's top-selling medicine by value in late 2025, recording roughly 100 crore rupees in sales in October alone. The premium market is already competitive, even as the generic market is just opening up.

The Export Opportunity Nobody Is Talking About Enough

The domestic price collapse is the headline. The export story is potentially the bigger one.

The expiration of semaglutide's patent across emerging economies and select regulated markets like Canada and Brazil could unlock a revenue pool exceeding 50,000 crore rupees for Indian generic drugmakers over the next decade. Multiple Indian pharmaceutical companies have already filed or expressed interest with the US FDA to sell generic semaglutide in America, where the patent holds until the early 2030s. The first filer in the US gets a 180-day exclusivity window, which at current Wegovy pricing would be an extraordinarily lucrative head start.

India has done this before. Two decades ago, when HIV antiretroviral drugs were priced at around 15,000 dollars per patient per year, Indian companies, most famously Cipla, slashed the price to approximately 350 dollars and made treatment accessible across sub-Saharan Africa and the developing world. That moment reshaped global health and India's reputation in the pharmaceutical industry permanently.

The semaglutide moment carries echoes of the same story. The molecule, the disease burden, the price barrier, and the Indian industry waiting on the other side of a patent wall. The dynamics are different in important ways. Semaglutide is a peptide and harder to manufacture consistently than small-molecule antiretrovirals. The regulatory hurdles in developed markets are more demanding. And the competition between Indian companies themselves will be intense. But the structural opportunity is similar.

The GLP-1 market in India alone, valued at roughly 1,000 to 1,200 crore rupees in 2025, is projected to grow to 4,500 to 5,000 crore rupees by 2030, according to CareEdge, a credit ratings and research firm. Add the export opportunity as patents fall in other countries, and the prize is one of the largest pharmaceutical opportunities India has seen in a long time.

The Part That Should Make Everyone Cautious

There is a version of this story where affordable access to a genuinely effective drug transforms healthcare outcomes for tens of millions of Indians. That version is possible.

There is also a version where a powerful injectable drug, poorly regulated, widely misused, and inconsistently manufactured, causes harm at scale. That version is also possible.

Semaglutide is not without side effects. The most common are gastrointestinal: nausea, vomiting, diarrhoea, constipation, bloating, and abdominal pain. These are typically mild, most pronounced during dose escalation, and affect up to half of patients in clinical trials. Rarer complications include gallstones and pancreatitis. The long-term effects of widespread use in populations that were not well-represented in clinical trials, including children, pregnant women, and people with advanced kidney disease, are not yet fully understood.

Semaglutide is also a peptide, a chain of amino acids, and peptide synthesis at industrial scale is technically demanding. Small variations in manufacturing quality can affect both how well the drug works and how safe it is. When 40 or more brands flood a market simultaneously, ensuring consistent manufacturing standards across all of them is genuinely hard, particularly in a country where the drug regulator has limited inspection capacity relative to the size of the industry it oversees.

The misuse problem is already visible, and the regulator has taken notice.

On March 11, 2026, nine days before the patent even expired, India's Drugs Controller General Rajeev Singh Raghuvanshi issued a formal advisory through the Central Drugs Standard Control Organisation. The directive told all pharmaceutical manufacturers and importers to immediately stop surrogate or indirect promotion of prescription drugs, with specific attention to weight-loss and metabolic disorder medicines.

What triggered it? Reports had surfaced that pharma companies, including global giants Eli Lilly and Novo Nordisk, were running multimedia awareness campaigns on social media and through influencer partnerships. Under India's Drugs and Cosmetics Act, prescription drugs cannot be advertised directly to the public. So companies had found a workaround: frame everything as disease awareness rather than product promotion. Create brand recall without technically naming the drug. The DCGI called it exactly what it was.

The advisory was unambiguous. Any promotion that exaggerates therapeutic efficacy, suggests guaranteed weight loss outcomes, downplays the role of diet and exercise, or creates product visibility through influencer engagement would be treated as misleading marketing and attract action under the Drugs Rules of 1945.

The CDSCO even marked a copy of the advisory to the Advertising Standards Council of India to ensure industry-wide compliance.

Dr. Ambrish Mithal, chairman of the endocrinology department at Max Hospital in Delhi, put it plainly. The science behind these drugs is very solid and they are extremely effective, he said, but they are not a clean solution and can have potential side effects. Because weight loss is such an attractive proposition, he noted, the surge in popularity likely drove the government to re-emphasize that these are not direct-to-public medications.

The concern is legitimate. Gym trainers, beauty clinics, and online pharmacies are already dispensing these drugs outside of proper medical supervision. As prices fall from 11,000 rupees to 1,300 rupees, the barrier to access collapses, and so does the barrier to misuse. A drug that requires careful dose escalation, dietary supervision, and ongoing medical monitoring does not become safer just because it becomes cheaper.

What This Moment Actually Is

Here is the honest framing.

The semaglutide patent expiry in India is one of the most consequential pharmaceutical events in recent memory, for the companies involved, for patients, and for the long-term trajectory of how India positions itself in global healthcare.

The scale of the opportunity is real. The need is real. The science behind the drug is real and expanding in ways that go well beyond weight loss. A molecule that started as a diabetes drug is now approved for heart disease, kidney disease, and liver disease, and researchers are actively investigating its potential in a dozen other conditions.

But affordable on paper is not the same as accessible in practice. And access without oversight is not healthcare. It is a market.

The Indian pharma companies that will win this race over the next five to ten years are not the ones that flood the market fastest with the cheapest vial. They are the ones that build physician trust, invest in patient education, deliver consistent product quality, and position themselves intelligently for the global generic opportunity as patents fall in Canada, Brazil, China, and eventually the United States.

The prescription paper said: come back after 20 March. The patients did.

Ninety million of them are still waiting.

Disclaimer: This article is for informational purposes only and should not be construed as medical or investment advice. Always consult a qualified healthcare professional before starting any medication.